TOday’s Movers: BioDelivery (NASDAQ:BDSI) Stock Rating Maintained at H.C. Wainwright; $3.5000 Target Price Indicates 53.85 % Potential

May 24, 2018 - By Rusty Cady

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Logo

Investors sentiment increased to 2.13 in 2017 Q4. Its up 0.46, from 1.67 in 2017Q3. It improved, as 4 investors sold BioDelivery Sciences International, Inc. shares while 11 reduced holdings. 15 funds opened positions while 17 raised stakes. 22.65 million shares or 11.32% more from 20.34 million shares in 2017Q3 were reported.

Guernsey-based Bluecrest Cap Management Ltd has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Baker Bros Advsr Limited Partnership holds 210,021 shares or 0.01% of its portfolio. State Bank Of Mellon holds 44,668 shares or 0% of its portfolio. Royal Retail Bank Of Canada reported 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Millennium Management Limited Liability owns 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 104,960 shares. Janney Montgomery Scott Limited Company holds 48,466 shares or 0% of its portfolio. Jpmorgan Chase Com invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Gru One Trading Limited Partnership has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Salem Investment Counselors holds 0.01% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 17,200 shares. Deutsche Fincl Bank Ag accumulated 154,964 shares or 0% of the stock. Barclays Public Ltd Company holds 72,386 shares or 0% of its portfolio. Virtu Fincl Ltd Llc reported 0.01% stake. Earnest Ltd Com accumulated 2,800 shares or 0% of the stock. Sigma Planning Corp holds 14,472 shares. Jacobs Levy Equity Mgmt holds 0.02% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 370,216 shares.

Since January 2, 2018, it had 0 insider buys, and 4 sales for $2.52 million activity. 64,155 BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares with value of $134,013 were sold by De Paolantonio Ernest Robert. $243,223 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) was sold by ODONNELL FRANCIS E JR.

BioDelivery (NASDAQ:BDSI) Rating Reaffirmed

New York: In an analyst note sent to investors and clients on Wednesday, 23 May, H.C. Wainwright restate their Buy rating on BioDelivery (NASDAQ:BDSI) shares. They now have a $3.5000 target price on the company. H.C. Wainwright’s target would indicate a potential upside of 53.85 % from the company’s last price.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 3 analysts covering BioDelivery (NASDAQ:BDSI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery has $5.0 highest and $400 lowest target. $4.50’s average target is 97.80% above currents $2.275 stock price. BioDelivery had 7 analyst reports since November 27, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of BDSI in report on Monday, November 27 with “Buy” rating. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, April 13. H.C. Wainwright has “Buy” rating and $400 target. Cantor Fitzgerald maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Thursday, March 15. Cantor Fitzgerald has “Buy” rating and $4.5 target. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Tuesday, February 6 by H.C. Wainwright. The firm earned “Buy” rating on Monday, May 7 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 19.

The stock decreased 1.09% or $0.025 during the last trading session, reaching $2.275. About 279,138 shares traded. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 10.53% since May 24, 2017 and is uptrending. It has underperformed by 1.02% the S&P500.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on August, 8. They expect $-0.21 earnings per share, up 22.22 % or $0.06 from last year’s $-0.27 per share. After $-0.18 actual earnings per share reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $134.85 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 25.28 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Nasdaq.com which released: “BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference” on May 23, 2018, also Globenewswire.com with their article: “BioDelivery Sciences Announces Pricing of $50 Million Equity Financing” published on May 17, 2018, Globenewswire.com published: “BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on …” on April 30, 2018. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Globenewswire.com and their article: “BioDelivery Sciences Appoints Herm Cukier as Chief Executive Officer” published on May 07, 2018 as well as Bizjournals.com‘s news article titled: “BDSI closes $50M equity financing – here’s what its board looks like now” with publication date: May 22, 2018.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.